Saturday 17 October 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 67.7% and free cash flow fell 13.0%, each against the same quarter a year earlier.
0.40
0.01
+2.56%
Follow BBLG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (54.96%) | (75.40%) | (70.17%) | (80.46%) |
+8 more TTM periods Free account |
|
| (50.55%) | (70.20%) | (64.38%) | (75.76%) | ||
ROIC |
0.00% | (1,340.96%) | (4,680.27%) | 0.00% | |
Return on Tangible Assets |
(73.66%) | (61.20%) | (57.81%) | (65.59%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.46) | (1.43) | (2.29) | (1.85) | |
Free Cash Flow |
(2.63) | (2.57) | (2.69) | (3.33) | |
| Other line items | |||||
Cash ROIC |
(33.04%) | (27.93%) | (25.12%) | (27.60%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.91 | 0.90 | 0.87 | 0.84 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.46) | (1.43) | (2.29) | (1.85) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates